Showing results (451-460 of 3,351) with videos related to
Sort By:
Pageof 336
The Lancet. Oncology|March 23, 2002
Cancer and the prothrombotic stateGregory Y H Lip, Bernard S P Chin, Andrew D BlannThe Lancet. Oncology|November 10, 2009
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalJames A Bonner, Paul M Harari, Jordi Giralt, et al.The Lancet. Oncology|November 3, 2009
First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009Ross A Soo, Benjamin O Anderson, Byoung Chul Cho, et al.The Lancet. Oncology|November 3, 2009
Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009Donald Poon, Benjamin O Anderson, Li-Tzong Chen, et al.The Lancet. Oncology|November 3, 2009
Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009Siriwan Tangjitgamol, Benjamin O Anderson, Hui Ti See, et al.The Lancet. Oncology|October 28, 2022
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trialHenry M Kuerer, Benjamin D Smith, Savitri Krishnamurthy, et al.The Lancet. Oncology|June 14, 2025
Therapeutic geographies of cancer in conflict: cancer care in IraqMac Skelton, Layth Mula-Hussain, Richard Sullivan, et al.The Lancet. Oncology|June 14, 2025
Towards a comprehensive cancer control policy in Saudi ArabiaSaleh A Alessy, Ali Al-Zahrani, Samar Alhomoud, et al.The Lancet. Oncology|July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trialVania Hungria, Paweł Robak, Marek Hus, et al.Pageof 336